Literature DB >> 10749460

Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization.

C Aebi1, F Theiler, C C Aebischer, M H Schoeni.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is associated with the appearance of serum autoantibodies directed against bactericidal/permeability-increasing protein (BPI).
OBJECTIVES: To determine the age-specific seroprevalence rates of anti-BPI-IgG and IgA in a population of patients with CF and to correlate anti-BPI antibody concentrations with microbial respiratory tract colonization and pulmonary function variables at the time of serum sampling and 6 years thereafter.
METHODS: Determination of BPI antibodies of the IgG and IgA isotypes using a commercial enzyme-linked immunosorbent assay in sera of a CF serum bank of 1992; correlation of anti-BPI antibody concentrations with age, clinical score, pulmonary function variables in 1992 and 1998, total serum immunoglobulin isotype concentrations and respiratory tract colonization with Pseudomonas aeruginosa and Aspergillus spp.
RESULTS: Seventy-one patients (age in 1992, 14.1 +/- 7.5 years) were studied. Reactivities for anti-BPI-IgG and IgA were found in 28 (39%) and 26 (37%) patients, respectively. The seroprevalence of anti-BPI-IgA, but not IgG, increased significantly with age. P. aeruginosa colonization was associated with elevated concentrations of anti-BPI-IgG (P = 0.003) and IgA (P = 0.037). There were significant negative correlations between pulmonary function variables (vital capacity, forced expiratory volume in 1 s) in 1992 and 1998, respectively, and concentrations of anti-BPI-IgG or IgA in a multiple regression analysis. Anti-BPI-IgG, but not IgA, remained significantly associated with P. aeruginosa colonization (P = 0.006) and with reduced vital capacity (P = 0.01) in 1998 after correction for total serum isotype concentration.
CONCLUSIONS: Anti-BPI-IgG are strongly associated with concurrent P. aeruginosa colonization and with long term restrictive pulmonary function abnormalities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749460     DOI: 10.1097/00006454-200003000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

Review 1.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

2.  Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.

Authors:  Diana Aichele; Markus Schnare; Marc Saake; Martin Röllinghoff; Andre Gessner
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

3.  Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram.

Authors:  Naidan Zhang; Jiaxiang Sun; Chaixia Ji; Xiao Bao; Chenliang Yuan
Journal:  Clin Rheumatol       Date:  2022-08-02       Impact factor: 3.650

4.  BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.

Authors:  H Schultz; S Schinke; J Weiss; V Cerundolo; W L Gross; S Gadola
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 5.  Prevalence of Bactericidal/Permeability-Increasing Protein Autoantibodies in Cystic Fibrosis Patients: Systematic Review and Meta-Analysis.

Authors:  Kenneth Iwuji; Eneko Larumbe-Zabala; Sharan Bijlani; Kenneth Nugent; Adaobi Kanu; Erena Manning; Ximena Solis
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 6.  Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; William F C Rigby
Journal:  J Transl Autoimmun       Date:  2021-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.